Financial Performance - The company's operating revenue for the current reporting period was ¥555,883,780.53, a decrease of 31.15% compared to the same period last year[2]. - The net profit attributable to shareholders of the listed company was ¥78,738,439.55, down 51.06% year-on-year[2]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was ¥64,423,011.00, reflecting a decline of 52.68% year-on-year[2]. - The basic and diluted earnings per share were both ¥0.25, a decrease of 50.98% compared to the same period last year[3]. - The company achieved a net profit of ¥357 million for the first three quarters of 2023, a year-on-year decline of 22.59%[4]. - The net profit attributable to the parent company for the third quarter was RMB 357.20 million, compared to RMB 461.45 million in the same period last year, reflecting a decrease of approximately 22.5%[39]. - The total comprehensive income for the third quarter was RMB 335.13 million, down from RMB 466.76 million year-on-year, indicating a decline of about 28.1%[39]. - The company reported a net profit of 365,645,845.17 yuan for the current period, down from 464,543,504.50 yuan in the previous period[64]. Revenue Breakdown - The life sciences segment generated revenue of ¥835 million, with core business revenue decreasing by 0.64% year-on-year[21]. - In the first three quarters of 2023, the company achieved operating revenue of RMB 1.826 billion, with a core business revenue growth of 11.35% after excluding the public health prevention business from the same period last year[54]. - The medical innovation segment achieved revenue of 986 million yuan in the first three quarters, with core business growing by 24.02% year-on-year[71]. - Domestic market revenue for the first three quarters reached CNY 1.21 billion, with core business growth of 17.15% year-on-year[84]. - Overseas market revenue for the first three quarters was CNY 608 million, showing a year-on-year growth of 1.05%, primarily impacted by project order delivery delays[84]. Research and Development - The total R&D investment was ¥85,076,764.84, an increase of 9.95% year-on-year, accounting for 15.3% of operating revenue[3]. - R&D, sales, and management expense ratios increased compared to the same period last year, due to the discontinuation of public health prevention business and increased R&D investment[72]. - The net profit after deducting non-recurring gains and losses decreased by 52.68% year-on-year, as the company increased R&D investment and market expansion efforts[58]. Cash Flow and Assets - The net cash flow from operating activities for the year-to-date was ¥167,496,285.23, a decrease of 13.45% compared to the same period last year[2]. - The company's total current assets as of September 30, 2023, amounted to RMB 2.64 billion, a decrease from RMB 3.49 billion at the end of 2022, representing a decline of approximately 24.4%[45]. - Cash and cash equivalents at the end of the third quarter of 2023 amounted to approximately CNY 1.28 billion, an increase from CNY 748.47 million at the end of the same period in 2022[81]. - The net cash flow from investing activities for the first three quarters of 2023 was approximately CNY 352.97 million, a significant improvement from a negative CNY 16.34 million in the same period of 2022[81]. - The company reported a total of CNY 4.65 billion in cash received from investment recoveries in the first three quarters of 2023, down from CNY 9.68 billion in the same period of 2022[81]. - The company’s total cash inflow from financing activities for the first three quarters of 2023 was CNY 8.40 million, compared to CNY 24.27 million in the same period of 2022[81]. Assets and Equity - The total assets as of September 30, 2023, were ¥5,492,366,972.02, a slight increase of 0.06% from the end of the previous year[12]. - The equity attributable to shareholders of the listed company was ¥4,207,513,559.88, up 4.65% from the end of the previous year[12]. - Total liabilities amounted to 1,075,023,932.18 yuan, a decrease from 1,340,645,397.33 yuan in the previous period[63]. - Total equity attributable to shareholders of the parent company increased to 4,207,513,559.88 yuan from 4,020,637,920.82 yuan in the previous period[63]. Future Outlook - The company plans to continue focusing on innovation and cost efficiency to drive future growth and improve profitability[54]. - The company is actively responding to macroeconomic challenges and is committed to enhancing its core business performance in the upcoming quarters[54]. - The company maintained a sufficient backlog of orders as of the end of the reporting period, indicating a stable outlook for future revenue generation[84].

证券代码：688139 证券简称：海尔生物 公告编号：2023-032 青岛海尔生物医疗股份有限公司 关于公司参与设立投资基金暨关联交易的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性依 法承担法律责任。 重要内容提示： 1、标的基金仍处于筹备设立阶段，尚未正式签署合伙协议，且尚需通 过市场监督管理部门及中国证券投资基金业协会等有关机构登记注册、备 案等手续，具体实施结果存在不确定性； 2、标的基金在后期运营过程中，所投资的项目受宏观经济、行业周期、 市场变化、投资标的公司经营管理、项目投资方案、监管政策等诸多因素 影响，可能存在无法达成投资目的、投资收益不及预期或亏损等风险。公 1 拟投资标的基金名称：青岛海创华资创业投资合伙企业（有限合伙）（最终 名称以工商登记的名称为准，以下简称"标的基金"、"基金"、"合伙企业" 或"本合伙企业"），重点投资于智能制造、生物医疗领域及与之相关产业 链上下游的创新型企业，与青岛海尔生物医疗股份有限公司（以下简称"海 尔生物"或"公司"）主营业务具有协同性。 拟投资金额：标的基金规模为人民币 21 ...

青岛海尔生物医疗股份有限公司 独立董事关于公司参与设立投资基金暨关联交易相关事项的 事前认可意见 根据《中华人民共和国公司法》《中华人民共和国证券法》《上海证券交易所 科创板股票上市规则》以及《青岛海尔生物医疗股份有限公司章程》《青岛海尔 生物医疗股份有限公司独立董事制度》等有关法律、法规、规章、规范性文件的 规定，我们作为青岛海尔生物医疗股份有限公司（以下简称"公司"）的独立董 事，认真审阅了《关于公司参与设立投资基金暨关联交易的议案》及相关事项发 表如下事前认可意见： 公司本次参与设立投资基金事项与公司主营业务具有协同性，符合公司的战 略发展需要。本次关联交易价格公允、合理，不存在损害公司和股东合法权益的 情形，不会对公司持续经营能力及公司独立性造成影响。我们一致同意将本议案 提交至公司董事会审议。 独立董事：陈洁、罗进、邹殿新、黄伟德 2023 年 10 月 26 日 ...

青岛海尔生物医疗股份有限公司 独立董事关于公司参与设立投资基金暨关联交易相关事项的 独立意见 根据《中华人民共和国公司法》《中华人民共和国证券法》《上海证券交易所 科创板股票上市规则》以及《青岛海尔生物医疗股份有限公司章程》《青岛海尔 生物医疗股份有限公司独立董事制度》等有关法律、法规、规章、规范性文件的 规定，我们作为青岛海尔生物医疗股份有限公司（以下简称"公司"）的独立董 事，认真审阅了《关于公司参与设立投资基金暨关联交易的议案》，基于独立、 客观判断的原则，发表独立意见如下： 经审议《关于公司参与设立投资基金暨关联交易的议案》，我们认为，就本 次交易事项，公司董事会已经履行关联交易表决程序，关联董事已回避表决，关 联交易定价公允、合理，不存在损害公司及全体股东特别是中小股东利益的行为， 不会影响公司的独立性。基于上述，我们同意公司参与设立投资基金暨关联交易 事项。 独立董事：陈洁、罗进、邹殿新、黄伟德 2023 年 10 月 26 日 ...

证券代码：688139 证券简称：海尔生物 公告编号：2023-031 青岛海尔生物医疗股份有限公司 第二届监事会第十五次会议决议公告 本公司监事会及全体监事保证本公告内容不存在任何虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性依 法承担法律责任。 一、监事会会议召开情况 青岛海尔生物医疗股份有限公司（以下简称"公司"、"本公司"或"海尔 生物"）第二届监事会第十五次会议于 2023 年 10 月 26 日以现场结合通讯方式 召开，现场会议在青岛市崂山区海尔盈康一生大厦 19 层会议室举行。本次会议 的通知于 2023 年 10 月 20 日以电子邮件方式送达全体监事。本次会议应出席监 事 3 人，实际出席监事 3 人，会议由监事会主席江兰主持。会议的召集和召开程 序符合有关法律法规、规范性文件和公司章程的规定，会议决议合法、有效。 二、监事会会议审议情况 本次会议由监事会主席江兰主持，经全体监事认真审议并表决，本次会议通 过了如下议案： （一）审议通过《关于审议公司 2023 年第三季度报告的议案》 经审议，我们作为公司监事认为：公司 2023 年第三季度报告的编制和审议 程序符合法 ...

Environmental Protection and Sustainability - The company invested 4.39 million yuan in environmental protection during the reporting period[3]. - The company reduced carbon dioxide equivalent emissions by 101.67 tons through carbon reduction measures[25]. - The company was recognized as a "National Green Factory" and included in the "2023 Carbon Neutral Model Enterprises" list[24]. - The company achieved multiple national energy-saving and environmental certifications for its products, including the US Energy Star certification[24]. - The company is focused on integrating green and innovative development concepts in its product design and manufacturing processes[24]. - The company has implemented internal procedures for pollutant control and hazardous waste management, ensuring compliance with national standards[21]. - The company has developed new products that assist in carbon reduction during the production process[25]. - The company has upgraded its manufacturing processes using advanced production technologies to reduce energy consumption[24]. - The company has established a comprehensive environmental management system from the board level to various functional departments[24]. - The company is committed to sustainable development through energy-efficient technologies and solutions in the medical and pharmaceutical sectors[6]. - The company is focusing on the development of new energy-efficient and low-carbon refrigeration technologies in response to increasing user demands for energy-saving and environmentally friendly products[121]. Financial Performance - The company's operating revenue increased by 0.2% year-on-year, with core business growth sustained and non-storage new industries maintaining rapid growth[43]. - Net profit attributable to shareholders decreased by 7.36% year-on-year, while net profit excluding non-recurring gains and losses decreased by 15.85%[43]. - Basic and diluted earnings per share both decreased by 7.37% year-on-year, primarily due to the cessation of public health prevention business and increased R&D investment[43]. - The company's operating revenue for the first half of the year was CNY 1,270,455,870.90, a slight increase of 0.20% compared to CNY 1,267,878,776.86 in the same period last year[55]. - Net profit attributable to shareholders decreased by 7.36% to CNY 278,462,841.61 from CNY 300,570,997.11 year-on-year[55]. - The net cash flow from operating activities dropped significantly by 38.38% to CNY 113,580,161.42 compared to CNY 184,335,005.22 in the previous year[55]. - The company's total assets at the end of the reporting period were CNY 5,489,422,045.01, showing a marginal increase of 0.01% from CNY 5,488,995,841.72 at the end of the previous year[55]. - Basic earnings per share decreased by 7.37% to CNY 0.88 from CNY 0.95 in the same period last year[55]. - Research and development expenses accounted for 12.40% of operating revenue, an increase of 1.84 percentage points compared to 10.56% in the previous year[55]. Research and Development - The company has developed eight major technology platforms and is actively integrating emerging technologies such as IoT, AI, and cloud computing into its solutions[59]. - The company has established eight major technology platforms, including refrigeration, automation, and separation, and holds 1,111 patents and 250 software copyrights[143]. - The company has established six major R&D and production centers to enhance its multidisciplinary integration and innovation capabilities[109]. - The company has developed a series of innovative low-temperature storage technologies, including a solar-powered vaccine storage system that can maintain vaccine safety for over 135 hours without power[5]. - The company has developed high-performance liquid nitrogen storage technology to reduce nitrogen consumption and achieve long-term low-temperature storage[7]. - The company has developed 4 new microbiological culture media products and is expanding its product line in laboratory reagents and consumables[138]. - The company has achieved industry-leading levels in plasma separation equipment and is developing automated blood component preparation products[139]. - The company has developed an IoT-based smart blood management system that significantly reduces blood transfusion times and improves safety for patients[128]. - The company has filed 306 new patent applications and received 243 patents, indicating a rapid increase in its intellectual property portfolio[133]. - The company’s R&D team is composed of top talents across multiple disciplines, driving innovation and user-centered product development[149]. - The company achieved a total R&D investment of ¥157,574,507.09, representing a 17.71% increase compared to the same period last year, with R&D expenses accounting for 10.56% of total revenue[155]. Market Expansion and Strategy - The company has established long-term partnerships with organizations like WHO and UNICEF, expanding its international market presence to over 40 countries and regions[59]. - The company is focusing on expanding its market presence in the life sciences and medical innovation sectors, leveraging its technological advancements[163]. - The company’s sales model primarily relies on distribution agreements, with a dedicated team for overseas market expansion[62]. - The company has expanded its overseas distributor network to over 800, serving users in more than 140 countries[189]. - The establishment of local warehousing centers in the Netherlands and the U.S. improved local delivery capabilities[191]. - The company achieved significant project deliveries in Ethiopia, Tanzania, and Cameroon, enhancing its international presence[189]. - The company is actively pursuing market expansion and innovation in response to the growing demand for automated and intelligent solutions in the life sciences sector[110]. Product Development and Innovation - New product offerings include comprehensive digital solutions for smart blood management and vaccination, enhancing the company's service portfolio in the healthcare sector[60]. - The company launched new products such as constant temperature incubators and high-capacity centrifuges to meet diverse user needs in cell culture, sterilization, and centrifugation preparation[131]. - The company has launched new products for blood stations, including platelet oscillators and plasma freezers, addressing the recovering user demand[172]. - The automated cell preparation solution developed by the company improved efficiency by 50%, providing a one-stop service for cell preparation processes[152]. - The company is developing a series of ultra-low temperature and low-temperature storage products with a total investment of ¥175,000,000, with significant progress in product development[158]. - The company has introduced an automated sample management platform, leading the industry in automated storage solutions[158]. - The company is focusing on digital transformation, moving from product sales to value-added services, enhancing user engagement and creating lifetime value[145]. - The company’s digital blood management solutions have upgraded from centralized to distributed blood supply models, ensuring "zero waiting" for hospital blood usage[183]. Industry Trends and Insights - The global life science tools market is expected to reach $161.57 billion in 2023, with a CAGR of 10.8% projected to $330.69 billion by 2030, driven by innovative policies and emerging biotechnologies[67]. - In the first half of 2023, national health expenditure reached ¥1,204 billion, a year-on-year increase of 6.9%, indicating sustained investment in healthcare infrastructure[70]. - The demand for smart laboratories in the life sciences sector is growing, with current penetration rates below 20%, indicating significant market potential[73]. - The government has set ambitious revenue targets for the biopharmaceutical industry, with annual R&D investment growth expected to exceed 10%[68]. - Continuous investment in medical infrastructure is emphasized, with a budget of ¥22.697 billion for health services in 2023, reflecting a 2.9% increase from the previous year[70]. - The industry is experiencing a shift towards domestic production, supported by local policies aimed at reducing reliance on imported products[74]. - The total investment in new medical infrastructure during the "14th Five-Year Plan" period is estimated at CNY 1,002.6 billion, focusing on high-quality public hospital development and grassroots healthcare[89].

经审阅《青岛海尔生物医疗股份有限公司 2023 年半年度募集资金存放与使 用情况专项报告》，我们认为：该报告真实反映了公司 2023 年半年度募集资金管 理与使用的相关情况。2023 年 1 月 1 日至 2023 年 6 月 30 日期间，公司对募集 资金进行了专户存储和专项使用，并及时履行了相关信息披露义务，不存在违反 法律法规改变募集资金用途和损害公司股东利益的情形。我们同意公司 2023 年 半年度募集资金存放与使用情况专项报告。 青岛海尔生物医疗股份有限公司 独立董事关于公司 2023 年半年度募集资金存放与使 用情况的独立意见 根据《中华人民共和国公司法》《中华人民共和国证券法》《上海证券交易所 科创板股票上市规则》以及《青岛海尔生物医疗股份有限公司章程》《青岛海尔 生物医疗股份有限公司独立董事制度》等有关法律、法规、规章、规范性文件的 规定，我们作为青岛海尔生物医疗股份有限公司（以下简称"公司"）的独立董 事，对公司编制的《青岛海尔生物医疗股份有限公司 2023 年半年度募集资金存 放与使用情况专项报告》进行了认真审阅，现基于独立判断的立场，发表如下独 立意见： 独立董事：陈洁、罗进、邹殿新、黄 ...

青岛海尔生物医疗股份有限公司（以下简称"公司"、"本公司"或"海尔 生物"）第二届监事会第十四次会议于 2023 年 8 月 29 日以现场结合通讯方式召 开，现场会议在青岛市高新区丰源路 280 号海尔生物医疗新兴产业园办公楼 101 举行。本次会议的通知于 2023 年 8 月 18 日以电子邮件方式送达全体监事。本次 会议应出席监事 3 人，实际出席监事 3 人，会议由监事会主席江兰主持。会议的 召集和召开程序符合有关法律法规、规范性文件和公司章程的规定，会议决议合 法、有效。 二、监事会会议审议情况 本次会议由监事会主席江兰主持，经全体监事认真审议并表决，本次会议通 过了如下议案： 证券代码：688139 证券简称：海尔生物 公告编号：2023-029 青岛海尔生物医疗股份有限公司 第二届监事会第十四次会议决议公告 本公司监事会及全体监事保证本公告内容不存在任何虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性依 法承担法律责任。 一、监事会会议召开情况 经审议，公司监事会认为：公司报告期内对募集资金的存放与使用符合《上 市公司监管指引第 2 号——上市公司募集资金管理和使用的监管 ...

证券代码：688139 证券简称：海尔生物 公告编号：2023-030 青岛海尔生物医疗股份有限公司 2023 年半年度募集资金存放与使用情况专项报告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性依 法承担法律责任。 一、募集资金基本情况 （一）实际募集资金金额、资金到账时间 经上海证券交易所科创板股票上市委员会于 2019 年 7 月 30 日审核同意，并 经中国证券监督管理委员会于 2019 年 9 月 20 日下发《关于同意青岛海尔生物医 疗股份有限公司首次公开发行股票注册的批复》（证监许可[2019]1742 号）核 准，青岛海尔生物医疗股份有限公司（以下简称"公司"、"本公司"或"海尔 生物"）公开发行人民币普通股 79,267,940 股，每股发行价格为人民币 15.53 元，募集资金总额为人民币 1,231,031,108.20 元，实际到账金额人民币 1,161,576,074.14 元，包括尚未划转的其他发行费用。上述募集资金于 2019 年 10 月 22 日到位，并经安永华明会计师事务所（普通合伙）审验并出具了《验资 ...

集体业绩说明会的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性依 法承担法律责任。 青岛海尔生物医疗股份有限公司 关于参加 2023 年半年度医疗器械及医疗设备行业 证券代码：688139 证券简称：海尔生物 公告编号：2023-028 投资者可于 2023 年 8 月 30 日（星期三）至 2023 年 9 月 4 日(星期一)16:00 前通过邮件（haierbiomedical@haierbiomedical.com）、电话（0532-88935566） 等方式将需要了解和关注的问题提前提供给公司。公司将在文字互动环节对投资者 普遍关注的问题进行回答。 青岛海尔生物医疗股份有限公司（以下简称"公司"）将于 2023 年 8 月 30 日 发布公司 2023 年半年度报告，为便于广大投资者更全面深入地了解公司 2023 年半 年度经营成果、财务状况、发展理念，公司参与了由上交所主办的 2023 年半年度 医疗器械及医疗设备行业集体业绩说明会，此次活动将采用网络文字互动的方式举 行，投资者可登录上海证券交易所上证路演中心（http: ...